510(k) device
EndeavorOTC
Akili Interactive Labs, Inc. · Digital Therapeutic Software For Attention Deficit Hyperactivity Disorder (QFT, Class II) · First FDA decision Jun 14, 2024, newest Jun 14, 2024ADHD
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
2
Naming "EndeavorOTC"
MAUDE reports
1
Brand "EndeavorOTC", since 2015
PubMed studies
0
Mentioning "EndeavorOTC"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing EndeavorOTC
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- EndeavorOTC510(k)
K233496 · Decided Jun 14, 2024 · 228 days after receipt
Device type: Digital Therapeutic Software For Attention Deficit Hyperactivity Disorder (QFT) · Obstetrics & Gynecology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "EndeavorOTC", any status and sponsor, newest update first.
- EndeavorOTC® Research Study in College StudentsStatus unknown
Akili Interactive Labs, Inc.Not on our public-company list
NCT06376032 · 69 participants · Start Jan 10, 2024 · Primary completion Dec 31, 2025
Device: EndeavorOTC® · For: Attention; Cognition; University Students
Sites: Cheektowaga, New York; Putney, Vermont
- EndeavorOTC™ Prospective Product RegistryActive, not recruiting
Akili Interactive Labs, Inc.Not on our public-company list
NCT06109051 · 198 participants · Start Oct 3, 2023 · Primary completion Dec 31, 2026
Device: EndeavorOTC · For: ADHD
Sites: Boston, Massachusetts
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "EndeavorOTC", and for the whole product code for context.
This brand
1 reports: 1 malfunction, 0 injury, 0 death
Whole product code QFT
2 reports: 2 malfunction, 0 injury, 0 death
Newest reports for this brand
- ENDEAVOROTCMalfunction
MW5146040 · Received Sep 21, 2023
Device type: Digital Therapeutic Software For Attention Deficit Hyperactivity Disorder (QFT)
Patient problem as coded: Nausea
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "EndeavorOTC"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code QFT.
- EndeavorRxAkili Interactive Labs, Inc. · De Novo 2023
- PrismiraLumos Labs, Inc. · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.